Research and Markets (http://www.researchandmarkets.com/research/80e919/peru_pharmaceutica) has announced the addition of the "Peru Pharmaceuticals and Healthcare Report Q3 2008" report to their offering.
Peru Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Peru's pharmaceuticals and healthcare industry.
Peru’s pharmaceutical market is continuing to display good growth. In 2008, forecasts that the market will expand by 11% in nominal terms. However, after factoring in inflation, the market will only grow by around 7% in real terms. Meanwhile, over the forecast period growth will start to tail off. This is a reflection of a similar trend regarding GDP, which will see real growth fall from 7% in 2008 to 3.9% in 2012. Meanwhile, due to the many challenges the country faces involving modernisation, as well as the impact that tighter intellectual property (IP) regulations will have on the market for unauthorised generics, the impact of the US-Peru Free Trade Agreement (FTA) will have a limited influence on the Peru’s drug sector during the forecast period. Nevertheless, over the longer term, BMI believes the agreement will be beneficial to the market, attracting greater investment and improving quality standards.
In the latest quarter the most important development has been the implementation of new laws regarding Intellectual Property. A bill approved by the country's Congressional Health Commission allows anyone convicted of selling, storing, packaging or producing substandard medicine to be imprisoned for up to 10 years. BMI supports tougher action on those that are involved in the counterfeit drug industry and believes it will help the country improve its business environment, helping to attract foreign investment. However, for the significant number of Peruvians existing beneath the poverty line, the removal of lowcost similares from the market could significantly impact access to medicines.
Patented drugs continue to dominate the market, taking a 70% share in value terms, a situation that BMI believes will only be reinforced by the recent FTA with the US and the strengthening of anti-counterfeit legislation. Leading therapeutic categories include cardiovascular drugs, followed by more basic treatments such as alimentary and metabolism drugs and anti-infectives. Due to Peru’s young population, there is not much market for drugs in disease areas intimately linked to ageing such as Alzheimer’s and certain types of cancer.
In Q308 Peru remains bottom of the Business Environment Ranking for the Americas region, for the most part due to the country’s low per capita spend on drugs, which in 2007 stood at just US$26.80. But strong growth could see it overtake close rivals such as Venezuela in the coming years.
Key Topics Covered:
Executive Summary
Peru: Pharmaceuticals And Healthcare Industry SWOT
Peru Political SWOT Analysis
Peru Economic SWOT Analysis
Peru Business Environment SWOT Analysis
Pharmaceutical Business Environment Ratings
Business Environment Rankings
Limits Of Potential Returns
Risks To Realisation Of Returns
Peru – Market Summary
Regulatory Regime
Intellectual Property Regime
Pricing And Reimbursement Issues
Other Regulatory Issues
Industry Developments
Epidemiology
Healthcare Sector
Pharmaceutical Sector
Industry Forecast Scenario
Table: Peru’s Drug Market Indicators, 2006-2012
Key Growth Factors – Industry
Table: Peru’s Health Expenditure Indicators
Key Growth Factors – Macroeconomic
A Shiny Outlook For Growth
table: PERU – ECONOMIC ACTIVITY
Patented Market Forecast
Table: Patented Market Indicators (US$mn unless otherwise stated)
OTC Market Forecast
Table: OTC Market Indicators (US$mn unless otherwise stated)
Generics Market Forecast
Table: Generic Market Indicators
Export/Import Forecasts
Table: Import/Export Trends (US$mn)
Other Healthcare Data Forecasts
Table: Other Healthcare Data Forecasts
Key Risks To BMI’s Forecast Scenario
Competitive Landscape
Table: Peruvian Pharmaceutical Companies That Acquired GMP Accreditation In 2006
Company Profiles
Leading Multinationals
Sanofi-Aventis
Merck & Co
GlaxoSmithKline
Novartis
Pfizer
Indigenous Manufacturer Profiles
Farmaindustria
Unimed
BMI Forecast Modelling
How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceutical Industry
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Weighting
Table: Weighting Of Components
Sources
Companies Mentioned:
- Sanofi-Aventis
- Merck & Co
- GlaxoSmithKline
- Novartis
- Pfizer
- Indigenous Manufacturer Profiles
- Farmaindustria
- Unimed
For more information visit http://www.researchandmarkets.com/research/80e919/peru_pharmaceutica
Contacts:
Laura Wood, Senior Manager
Fax from USA:
646-607-1907
Fax from rest of the world: +353-1-481-1716
press@researchandmarkets.com
